Enamine and BioSolveIT Launch the World's Largest Searchable Chemical Space for Novel Compound Sourcing
Enamine Ltd., a leading chemical research organization and producer of the world’s largest collections of novel building blocks (150,000) and screening compound libraries (2,400,000), and BioSolveIT GmbH, premium provider of medicinal chemistry software, today announced the launch of the ‘REAL Space Navigator’. Jointly developed, the new software tool capitalizes on Enamine’s REAL (readily accessible) virtual compound concept and provides efficient ‘search & find’ access to more than 640 million pharma-oriented molecules, to date the world's largest chemical space of commercially accessible compounds.
Searching databases of commercially available compounds is a standard approach to advance hit compounds. However, the global stock of screening compounds has already been largely explored, making the identification of new and promising lead molecules difficult and the need for fast access to novel compounds increasingly necessary.
Enamine can quickly and efficiently assemble new compounds through appropriate single step combinations of the 150,000 building blocks available in its stock. By selecting the most characterized of these and proving their utility in parallel synthesis using 106 reaction protocols developed at Enamine, the Company confidently ensures a minimum synthesis rate of 80% and delivery time of 3-4 weeks. BioSolveIT’s unique software capabilities have allowed for the searchability of a huge virtual chemical space that would be a challenge to navigate using traditional search technologies. REAL Space Navigator can be easily deployed on a standard computer, allowing for convenient, ultra-fast similarity searches and scaffold hopping without the need to connect to the internet and potentially disclose confidential queries.
Michael Bossert, Head of Strategic Alliances at Enamine, commented: “The drug discovery industry has an enormous interest in new chemical compounds. Our REAL concept provides an efficient solution for virtual screening initiatives and analog searches to our clients, who appreciate going beyond the availability bias. BioSolveIT’s fantastic team and its exceptional software platforms have already expanded the borders of Enamine’s REAL database. We will continue to evolve this and hope to put billions of our future tangible molecules at researchers’ fingertips. ”
Dr. Christian Lemmen, CEO of BioSolveIT, explained: “Our technology is based on extremely fast tree-based algorithms that avoid visiting every virtual molecule while traversing vast chemistry spaces for interesting hits. With Enamine's outstanding experience in chemical syntheses and quality-driven selection of building blocks, that space is not only impressively large but also packed with unique chemical matter. We are proud to be Enamine's partner in this exciting endeavor and thus offer users of the REAL Space Navigator a considerable competitive advantage. ”
Both Companies continue to collaborate with plans to grow the database beyond 1 billion compounds by Q2 2018.
For further information on the REAL Space Navigator: http://www.enamine.net/index.php?option=com_content&id=259
Sarah Jeffery, +44 7771 730919
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
VERTEX-PHARMACEUTICALS19.10.2018 13:56 | pressemeddelelse
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene
TX-SCHLUMBERGER-LIMITED19.10.2018 13:02 | pressemeddelelse
Schlumberger Announces Third-Quarter 2018 Results
CA-TRADESHIFT19.10.2018 13:02 | pressemeddelelse
Tradeshift Announces Q3 2018 Results
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum